Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves’ Orbitopathy

다국어 초록 (Multilingual Abstract)

Purpose: Chemokines are involved in the pathogenesis of various autoimmune diseases, including Graves’ orbitopathy (GO), but comprehensive analyses of the dynamics of these cytokines and their receptors in such diseases remain lacking. In this study, we investigated the expressions of chemokines and their receptors during adipogenesis and inflammation in primary cultured orbital fibroblasts from patients with GO.
Methods: The messenger RNA (mRNA) expression levels of chemokines were compared between GO (n = 6) and non-GO (n = 5) orbital tissues by real-time polymerase chain reaction. After adipogenesis was induced in primary cultured orbital fibroblasts from patients with GO (n =5) and following stimulation with interleukin (IL)-1β and tumor necrosis factor (TNF)-α, the mRNA expression levels of chemokines and their receptors were analyzed.
Results: Chemokines were significantly downregulated in GO orbital tissues compared to non-GO orbital tissues (p < 0.05). Adipogenesis resulted in a strong increase in mRNA expression levels of chemokines and their receptors at an early stage (day 1); however, expression levels started to decrease thereafter and, eventually, decreased to below basal levels at the end of adipogenesis (day 10). Following stimulation with IL-1β and TNF-α, the mRNA expression levels of chemokines and their receptors increased, showing different responses to various proinflammatory cytokines.
Conclusions: Chemokines were strongly upregulated in the early phase of adipogenesis before decreasing continuously until the end of adipogenesis. Also, overt mature GO tissues showed reduced mRNA expression of chemokines compared to controls, which might indicate the existence of a shorter window for effective medical inflammatory treatment. The heightened levels of chemokines and their receptors observed after stimulation with IL-1β and TNF-α suggest a crucial role of proinflammatory cytokines in the pathogenesis of GO and, further, support the idea that chemokines could be used as biomarkers of GO activity.

참고문헌 (Reference)

1 Antonelli A, "β(CCL2)and α(CXCL10)chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves’ ophthalmopathy" 213 : 183-191, 2012

2 Theofilopoulos AN, "The role of IFN-gamma in systemic lupus erythematosus : a challenge to the Th1/Th2 paradigm in autoimmunity" 3 : 136-141, 2001

3 Charo IF, "The many roles of chemokines and chemokine receptors in inflammation" 354 : 610-621, 2006

4 Smith TJ, "Teprotumumab for Thyroid-Associated Ophthalmopathy" 376 : 1748-1761, 2017

5 Han R, "T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts : implications for the pathogenesis of thyroid-associated ophthalmopathy" 147 : 13-19, 2006

6 Pappa A, "T cells a nd f ibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy" 84 : 517-522, 2000

7 Seo Y, "Sphingosine-1-phosphate is involved in inf lammatory reactions in patients with Graves’ orbitopathy" 66 : 535-545, 2017

8 Narumi S, "Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus" 12 : 1561-1565, 2000

9 Hiromatsu Y, "Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy" 12 : 217-221, 2002

10 Yoon JS, "Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves’ orbitopathy" 6 : e26261-, 2011

11 Garrity JA, "Pathogenesis of graves ophthalmopathy:implications for prediction, prevention, and treatment" 142 : 147-153, 2006

12 Antonelli A, "Monokine induced by interferon gamma(IFNgamma)(CXCL9)and IFNgamma inducible T-cell alpha-chemoattractant(CXCL11)involvement in Graves’ disease and ophthalmopathy : modulation by peroxisome proliferator-activated receptor-gamma agonists" 94 : 1803-1809, 2009

13 Kim JW, "Is modified clinical activity score an accurate indicator of diplopia progression in Graves’ orbitopathy patients" 63 : 1133-1140, 2016

14 Bahn RS, "Graves’ ophthalmopathy" 362 : 726-738, 2010

15 Wenzel J, "Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus" 205 : 435-442, 2005

16 Salvi M, "Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy : a randomized controlled study" 100 : 422-431, 2015

17 de Carli M, "Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves’ ophthalmopathy" 77 : 1120-1124, 1993

18 Hiromatsu Y, "Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy" 85 : 1194-1199, 2000

19 Dik WA, "Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy" 142 : 83-91, 2016

20 Bahn RS, "Current insights into the pathogenesis of Graves’ophthalmopathy" 47 : 773-778, 2015

21 Mysliwiec J, "Circulating CXCL9 and CXCL10 as markers of activity of Graves’ orbitopathy during treatment with corticosteroids and teleradiotherapy" 44 : 957-961, 2012

22 Antonelli A, "Chemokine(C-X-C motif)ligand(CXCL)10 in autoimmune diseases" 13 : 272-280, 2014

23 Kabir SM, "Chemokine network during adipogenesis in 3T3-L1 cells: Differential response between growth and proinflammatory factor in preadipocytes vs. adipocytes" 3 : 97-106, 2014

24 Livak KJ, "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T))Method" 25 : 402-408, 2001

25 Wiersinga WM, "Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy" 5 : 134-142, 2017